Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

AIMS: There is robust trial evidence for improved overall survival (OS) with immunotherapy in advanced solid organ malignancies. The real‐world long‐term survival data and the predictive variables are not yet known. Our aim was to evaluate factors associated with 3‐year and 5‐year OS for patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Lauren J, da Silva, Ines Pires, Moujaber, Tania, Gao, Bo, Hui, Rina, Gurney, Howard, Carlino, Matteo, Nagrial, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067054/
https://www.ncbi.nlm.nih.gov/pubmed/36404632
http://dx.doi.org/10.1002/cam4.5468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067054/
https://www.ncbi.nlm.nih.gov/pubmed/36404632
http://dx.doi.org/10.1002/cam4.5468

Ejemplares similares